Inflammatory Disease Biotech Kymera Launches $125M IPO
Kymera Therapeutics on Monday readied a $125 million initial public offering with help from Goodwin Procter LLP and WilmerHale, as the biotechnology company looks to fund clinical trials for treatments of...To view the full article, register now.
Already a subscriber? Click here to view full article